The influence of age and sex on the clearance of cytochrome P450 3A substratesCOTREAU, Monette M; VON MOLTKE, Lisa L; GREENBLATT, David J et al.Clinical pharmacokinetics. 2005, Vol 44, Num 1, pp 33-60, issn 0312-5963, 28 p.Article

A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin)COTREAU, Monette M; STONIS, Lucille; STRAHS, Andrew et al.Biopharmaceutics & drug disposition. 2004, Vol 25, Num 7, pp 291-296, issn 0142-2782, 6 p.Article

Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal womenCOTREAU, Monette M; STONIS, Lucille; DYKSTRA, Kevin H et al.Journal of clinical pharmacology. 2002, Vol 42, Num 2, pp 157-165, issn 0091-2700Article

Comparison of Human and Rat Uterine Leiomyomata: Identification of a Dysregulated Mammalian Target of Rapamycin PathwayCRABTREE, Judy S; JELINSKY, Scott A; DAVE, Bhuvanesh et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 15, pp 6171-6178, issn 0008-5472, 8 p.Article

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid TumorsESKENS, Ferry A. L. M; DE JONGE, Maja J. A; VERWEIJ, Jaap et al.Clinical cancer research (Print). 2011, Vol 17, Num 22, pp 7156-7163, issn 1078-0432, 8 p.Article

A study of 17p-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophyCOTREAU, Monette M; CHENNATHUKUZHI, Vargheese M; CRABTREE, Judy S et al.Maturitas (Amsterdam). 2007, Vol 58, Num 4, pp 366-376, issn 0378-5122, 11 p.Article

The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humansCOTREAU, Monette M; WARREN, Sarah; RYAN, John L et al.Journal of clinical pharmacology. 2003, Vol 43, Num 10, pp 1108-1115, issn 0091-2700, 8 p.Article